Dual Antiplatelet Therapy for Heart Disease Print ISSN: 0009-7322. Online ISSN: 1524-4539 Copyright © 2014 American Heart Association, Inc. All rights reserved. is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231 Circulation doi: 10.1161/CIRCULATIONAHA.113.004305 2014;129:e506-e508 Circulation. http://circ.ahajournals.org/content/129/21/e506 World Wide Web a...

We have read with great interest the article by Dr. Bassas et al regarding the use of antiplatelet and anticoagulant treatment in dermatological surgery. We would like to congratulate the authors on their excellent and exhaustive review.1 We agree with their conclusion: there is no scientific evidence supporting the withdrawal of antiplatelet therapy in dermatological surgery settings, and it i...

In 2016, dual antiplatelet therapy (DAPT) assumes its 20th anniversary since the publication of the first randomized clinical trial establishing the superiority of DAPT over anticoagulant therapy among patients undergoing percutaneous coronary intervention (PCI) (Figure). Because then, both antiplatelet therapy and PCI have undergone continued refinement. Clopidogrel substituted ticlopidine, an...

In 2016, dual antiplatelet therapy (DAPT) assumes its 20th anniversary since the publication of the first randomized clinical trial establishing the superiority of DAPT over anticoagulant therapy among patients undergoing percutaneous coronary intervention (PCI) (Figure). Because then, both antiplatelet therapy and PCI have undergone continued refinement. Clopidogrel substituted ticlopidine, an...

BACKGROUND Prasugrel and ticagrelor are two new antiplatelet agents being used in the management of acute coronary syndromes. The number of patients in the community managed on these medications is growing, and thus, it is essential that general practitioners have a good understanding of these agents and their evidence-based applications. OBJECTIVE The pharmacokinetic and pharmacodynamic prop...